ACTR-12. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Current standard-of-care for glioblastoma (GBM) includes surgery followed by concurrent therapy with radiation and temozolomide (TMZ) followed by adjuvant TMZ (days 1–5 every 28 days. Almost all GBM patients experience recurrent/progressive disease, with a median survival after recurrence of 3–9 mon...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: O’Brien, Barbara, Penas-Prado, Marta, Kamiya, Carolos, Pei Weathers, Shiao-, Yung, Alfred, Loghin, Monica, Harrison, Rebecca, Bacha, Jeffrey, Brown, Dennis, Johnson, Gregory, Langlands, John, Schwartz, Richard, Kanekal, Sarath, Lopez, Lorena, deGroot, John
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Adult Clinical Trials - Non-Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846869/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.055
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars